Calidi Biotherapeutics Shares Set to Reverse Split on Friday, July 31st (NYSEAMERICAN:CLDI)

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI)’s stock is scheduled to reverse split before the market opens on Friday, July 31st. The 1-16 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, July 30th.

Calidi Biotherapeutics Trading Up 6.1%

Shares of CLDI opened at $0.11 on Thursday. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.92 and a quick ratio of 1.92. The firm has a 50 day simple moving average of $0.16 and a 200-day simple moving average of $0.44. Calidi Biotherapeutics has a 1-year low of $0.10 and a 1-year high of $10.92. The stock has a market cap of $2.04 million, a price-to-earnings ratio of -0.02 and a beta of 1.30.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.43) earnings per share (EPS) for the quarter.

Institutional Trading of Calidi Biotherapeutics

Several institutional investors and hedge funds have recently made changes to their positions in CLDI. Virtu Financial LLC acquired a new stake in shares of Calidi Biotherapeutics during the fourth quarter valued at $25,000. Geode Capital Management LLC increased its position in Calidi Biotherapeutics by 41.7% during the 4th quarter. Geode Capital Management LLC now owns 41,929 shares of the company’s stock worth $49,000 after purchasing an additional 12,334 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in Calidi Biotherapeutics in the 4th quarter valued at about $173,000. 12.53% of the stock is currently owned by hedge funds and other institutional investors.

About Calidi Biotherapeutics

Calidi Biotherapeutics is a clinical-stage biotechnology company focused on the development of targeted immunotherapies that harness the body’s innate immune system to treat cancer and infectious diseases. By delivering proprietary RNA-based immune stimulants directly into the tumor microenvironment or sites of infection, Calidi aims to trigger a robust local immune response while minimizing systemic toxicity. The company’s platform is designed to engage multiple innate immune pathways, including toll-like receptors and RIG-I-like receptors, to initiate durable antitumor and antiviral activity.

Calidi’s lead oncology programs include CB-012, an intravesical therapy in clinical development for non-muscle invasive bladder cancer, and CB-013, an intratumoral candidate targeting a range of advanced solid tumors.